RAPT Therapeutics, Inc.

Money Moves

Being acquired by GSK; deal expected to close Q1 2026

For decades, the 27 million American adults and children with food allergies had one option: avoid the allergen and carry an EpiPen. That changed in February 2024 when the FDA approved Xolair as the first drug to reduce allergic reactions—including anaphylaxis—from accidental exposure to multiple foods.

Updated May 22